Pharmacological evidence for lack of central effects of reserpine methonitrate: A novel quaternary analog of reserpine

Therapy

Volumn 1, Issue 2, 2004, Pages 231-239

  Nammi, Srinivas ^a   Boini, Krishna M ^b   Kilari, Eswar K ^b   Sreemantula, Satyanarayana ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ANDHRA UNIVERSITY   (India)

Author keywords

Behavior; Blood pressure; Mice; Rats; Reserpine; Reserpine methonitrate

Indexed keywords

BARBITURIC ACID DERIVATIVE; CATECHOLAMINE; DIMETHYL SULFOXIDE; RESERPINE; RESERPINE DERIVATIVE; RESERPINE METHONITRATE; THIOPENTAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DEPRESSION; CONDITIONED REFLEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SYNTHESIS; DRUG TARGETING; EYELID MOVEMENT; FEMALE; HYPNOSIS; HYPOTENSION; HYPOTHERMIA; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM FUNCTION; RAT; STATISTICAL SIGNIFICANCE; TRANQUILIZING ACTIVITY;

EID: 23844473255     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.1.2.231     Document Type: Article

References (57)

1. Lin HC, Yu PC, Lee SD, Tsai YT, Kuo JS, Yang MC. Effects of reserpine administration in two models of portal hypertension in rats. J. Hepatol. 19, 413-417 (1993).
2. Zeng GY, Xie SY, You SQ, Jin YC. Effects of reserpine on the development of neuropsychogenic hypertension in dogs. Sci. Sin. 23, 796-802 (1980).
3. Magarian GJ. Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension? Gen. Intern. Med. 6, 561-572 (1991).
4. Nasrallah HA, Risch SC, Fowler RC. Reserpine, serotonin, and schizophrenia. Am. J. Psychiatry. 136, 856-857 (1979).
5. Pittrow DB, Krönig B, Kirch W, Weidinger G. Evaluation of reserpine and clopamid alone or in combination for first-line treatment of hypertension. Am. J. Hypertension. 9, 144 (1996).
6. Fries ED. Reserpine in hypertension: present status. Am. Fam. Physician. 11, 120-122 (1975).
7. Ganett RL, Canver O Jr, Douglas BH. Effects of reserpine on blood pressure and vascular electrolytes in hypertension. Eur. J. Pharmacol. 2, 236-238 (1967).
8. Smith WM, Thurm RH, Brown LA, Comparative evaluation of Rauwolfia whole root and reserpine. Arch. Int. Pharmacodyn. Ther. 151, 76-85 (1969).
9. Rudnick G, Steiner-Mordoch SS, Fishkes H, Stern-Bach Y, Schuldiner S. Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29, 603-608 (1990).
10. 2+-ATP dependent storage mechanism in the amine granules of the adrenal medulla. Acta Physiol. Scand. 59, 1-38 (1963).
11. Baumeister AA, Hawkins MF, Uzelac SM. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J. Hist. Neurosci. 12, 207-220 (2003).
12. Lewis H, Bacher N. Early reserpine sensitivity and depression in schizophrenia. J. Clin. Psychopharmacol. 1, 409-410 (1981).
13. Torre E, Ancona M, Scotto G. Reserpine and depression. Clinical cases Minerva Psychol. 26, 87-89 (1985).
14. Muscholl E, Vogt M. The action of reserpine on the peripheral sympathetic system. J. Physiol. 141, 132-155 (1958).
15. Brodie BB, Finer KF, Orlans FB, Quinn GF, Sulser F. Evidence that tranquilizing action of reserpine is associated with change in brain serotonin. J. Pharmacol. Exp. Ther. 129, 250-256 (1960).
16. Lemieux G, Davignon A, Genest J. Depressive states during Rauwolfia therapy for arterial hypertension: A report of 30 cases. Can. Med. Ass. J. 74, 522-528 (1956).
17. Harris TH. Depression induced by Rauwolfia compounds. Am. J. Psychiat. 113, 950 (1957).
18. Noce RH, Williams DB, Rapaport W. Reserpine (Serpasil) in the management of mentally ill and mentally retarded. J. Am. Med. Assoc. 156, 821 (1954).
19. Hughes WM, Moyer JH, Daeschner WC. Parenteral reserpine in treatment of hypertensive emergencies. Arch. Int. Med. 95, 563-577 (1955).
20. Plummer AJ, Earl A, Schneider A, Trapold J, Barrett W. Pharmacology of Rauwolfia alkaloids, including reserpine. Ann. NY Acad. Sci. 59, 8-21 (1954).
21. Schneider JA. Further characterization of central effects of reserpine (serpasil). Am. J. Physiol. 181, 64-68 (1955).
22. Shore PA, Silver SL, Brodie BB. Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia 11, 272-273 (1955).
23. Salmoiraghi GC, Sollero L, Page IH. Blockade by Brom-lysergic acid diethylamine (BOL) of the potentiating action of serotonin and reserpine on hexobarbital hypnosis. J. Pharmacol. Exp. Ther. 117, 166-168 (1956).
24. Beim HJ, Brunner H. Antihypertensive therapy: Principles and Practice. Gross F (Ed.), Springer, Berlin 15 (1966).
25. Kastin AJ, Honour LC, Sueiras-Diaz J, Coy DH. Opposite effects of CRF and ACTH on reserpine-induced hypothermia. Pharmacol. Biochem. Behav. 17, 1203-1206 (1982).
26. 2 adrenergic receptors. Pharmacol. Biochem. Behav. 27, 21-24 (1987).
27. Matsuoka M, Yoshida H, Imaizumi R. Correlation between brain catecholamine and sedative action of reserpine. Nature 202, 198 (1964).
28. Pirch JH, Rech RH. Behavioral recovery in rats during chronic reserpine treatment. Pychopharmacologia 12, 115-122 (1968).
29. Walsh TJ, Palfai T. Time-dependent effects of reserpine on retention of passive avoidance. Pharmacol. Biochem. Behav. 8, 103-105 (1978).
30. Funk KF, Schimidt J, Westermann KH. Central depletion of transmitters by reserpine and motor behavior in the rat. Acta Biol. Med. Ger. 39, 923-927 (1980).
31. Palfai T, Wichlinski L, Brown OM. The effect of reserpine, syrosingopine and guanethidine on the retention of discriminated escape reversal: peripherally administered catecholamines cannot reverse the reserpine amnesia in this situation. Behav. Neural. Biol. 38, 120-126 (1983).
32. Garatfini S, Mortari A, Valsecchi A, Valzelli L. Reserpine derivatives with specific hypotensive or sedative activity. Nature 183, 1273-1274 (1959).
33. Agbalyam SG. Synthetic analogs of reserpine. Uspek Khim 30, 1175-1195 (1961).
34. Karim MA, Linnell WH, Sharp LK. Potential reserpine analogues Part II. 3,4,5-trimethoxybenzoic acid derivatives. J. Pharm. Pharmacol. 12, 82-86 (1961).
35. Protiva M, Rajsner M, Jilek JO. Synthesis in the Group of Hypotensive Alkaloids XIII. Synthesis of dl-10-methyldeserpidine, dl-10-ethoxydeserpidine and dl-10-methylthiodeserpidine. Monat Chem. 91, 703-716 (1960).
36. Trcka V, Carlsson A. Mediodespidine, hypotensive reserpoid without sedative effiect. II. Effect on monoamine levels in mouse organs. Life Sci. 4, 2263-2267 (1965).
37. Trcka V, Carlsson A. Pharmcology of reserpine analogues VI. Reserpine analogs with differential effect on brain monoamines. Acta Physiol. Toxicol. 25, 107-112 (1967).
38. Lapin IP. Pharmacological activity of quaternary derivatives of iminodibenzyl and phenothiazine as an approach to the demarcation of peripheral and central effects of antidepressants and neuroleptics. Sov. Psikhotrop. Sredstve. 120-125 (1970).
39. Brewster ME, Biegon A, Degani H, Pop E. Mechanisms of action of quaternary derivatives of tamoxifen. Book of abstracts, 212 ACS National Meeting. Washington DC, USA, MEDI043 (1996).
40. Janosky DS. Central anaticholinergics to treat nerve-agent poisoning. Lancet 359, 25-256 (2002).
41. Schlittler E. Methyl O-(lower alkanoyl) reserpates. US3,169,967 (1965). [Chem. Abstr. 62: 16320 (1965)].
42. 3-epimerization of reserpine and deserpidine. Tetrahedron 23, 4053-4063 (1967).
43. Varma RK, Kaushal R, Thomas GP, Junnarkar AY, Singh PP, Tripathi RM. Evaluation of dimethyl sulfoxide as a solvent in pharmacological experiments. Ind. J. Exp. Biol. 25, 758-760 (1987).
44. Kuhn WL, Van Maanen EF. Central nervous system effects of thalidomide. J. Pharmacol. Exp. Ther. 134, 60-68 (1961).
45. Turner RA. Screening Methods in Pharmacology. Turner RA(Ed.), Academic Press, London, 22-34 & 61-62 (1965).
46. Cook L, Weidley E. Behavioral effects of some psychopharmacological agents. Ann. NY Acad. Sci. 66, 740-752 (1957).
47. Noble A. The rat blood pressure preparation. In: Experiments in Physiology and Biochemistry, Kernut GA (Ed.), Academic Press, London, UK 6, 1-32 (1973).
48. Lapin IP. Pharmacological activity of quaternary derivatives of imipramine and (diethylaminopropionyl)iminodibenzyl. Pharmakopsychiat. Neuropsychopharmakol. 2, 14-27 (1969).
49. Xue-feng P, Qian-sheng Y, Holloway HW, Arnold B, Greig NH. Synthesis and biological evaluation of ring-opened analogs of the cholinesterase inhibitors of physostigmine, phenserine and cymserine. Med. Chem. Res. 9, 50-60 (1999).
50. Shore PA, Pletscher A, Tomich E, Carlsson A, Kuntzman R, Brodie BB. Role of brain serotonin in reserpine action. Ann. NY Acad. Sci. 66, 609-615 (1957).
51. Trendelenburg U. Supersensitivity and sensitivity to sympathomimetic amines. Pharmacol. Rev. 15, 225-276 (1963).
52. Brodie B, Shore PA. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann. NY Acad. Sci. 66, 631-642 (1957).
53. Jarvinen M, Jarvinen A, Torsti P. Effect of reserpine on heart rate and blood pressure during exercise. Ann. Med. Exp. Biol. Fenn. 44, 408-410 (1966).
54. Khatri CK, Qayum A, Yusuf SM. Comparative studies on the effects of reserpine and its derivatives (bromo and dibromo) reserpine on the blood pressure, heart rate and EEG of rabbit. J. Pak. Med. Assoc. 32, 141-144 (1982).
55. Krogsgaard AR. Hypotensive effect of reserpine compared with Phenobarbital and placebo. Acta Med. Scand. 157, 379-385 (1957).
56. Burn JH, Rand MJ. Noradrenaline in artery walls and its dispersal by reserpine. Br. Med. J. I(5076), 903-908 (1958).
57. Paasonen MK, Krayer O. The release of norepinephrine from the mammalian heart by reserpine. J. Pharmacol. Exp. Ther. 123, 153-160 (1958).